OncoMatch/Clinical Trials/NCT04146298
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Is NCT04146298 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Mutant KRAS G12V-specific TCR transduced autologous T cells and Cyclophosphamide for pancreatic cancer.
Treatment: Cyclophosphamide · Fludarabine · Mutant KRAS G12V-specific TCR transduced autologous T cells · Anti-PD-1 monoclonal antibody — This clinical trial will evaluate the safety and activity of mutant KRAS G12V-specific TCR transduced T cell therapy for advanced pancreatic cancer patients who express the KRAS G12V mutation and HLA-A\*11:01 allele. The theoretical basis of this study is that mutant KRAS antigen-specific TCR transduced autologous Tcells will target and kill HLA-matched mutant KRAS cancer cells but not normal cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS G12V
Patient's tumor must express the KRAS G12V mutation
Required: HRAS G12V
or a G12V mutation in HRAS ... as determined by DNA or RNA sequencing methods
Required: NRAS G12V
or a G12V mutation in ... NRAS, as determined by DNA or RNA sequencing methods
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard chemotherapy
who have received standard chemotherapy
Must have received: surgery and adjuvant chemotherapy
who have received surgery and adjuvant chemotherapy previously
Lab requirements
Blood counts
absolute neutrophil count >= 1000/mm^3; white blood cell count >= 3000/mm^3; platelet count >= 100,000/mm^3; hemoglobin > 8.0 g/dl
Kidney function
serum creatinine <= 1.6 mg/dl
Liver function
serum alt/ast <= 3.0 x uln; total bilirubin <= 1.5 mg/dl (<= 3.0 mg/dl if gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify